Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia

Bone Marrow Transplantation

Volumn 45, Issue 6, 2010, Pages 1047-1051

  Frugnoli, I ^a   Cappelli, B ^a,b   Chiesa, R ^a,b   Biral, E ^a,b   Noe A ^a   Evangelio, C ^a   Fossati, M ^a   Napolitano, S ^a   Ciceri, F ^a   Roncarolo, M G ^a,b,c   Marktel, S ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

donor lymphocytes infusion (DLI); graft failure; mixed chimerism; rejection; thalassemia

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; BETA THALASSEMIA; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOPENIA; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; MALE; NEUTROPENIA; PANCYTOPENIA; PATIENT SAFETY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL TRANSPLANTATION; THALASSEMIA; THROMBOCYTOPENIA; BETA-THALASSEMIA; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MALE; MYELOABLATIVE AGONISTS; TRANSPLANTATION CHIMERA; TREATMENT OUTCOME;

MYELOABLATIVE AGENT;

EID: 77954860564     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.298     Document Type: Article

References (29)

1. Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22: 53-63.
2. Nesci S, Manna M, Andreani M, Fattorini P, Graziosi G, Lucarelli G. Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 143-146.
3. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 8: 3494-3499.
4. Andreani M, Testi M, Battarra M, Indigeno P, Guagnano A, Polchi P et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus 2008; 6: 143-149.
5. Gaziev J, Sodani P, Lucarelli G, Polchi P, Marktel S, Paciaroni K et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant 2008; 42: 397-404.
6. Elmaagacli AH, Beelen DW, Trenn G, Schmidt O, Nahler M, Schaefer UW. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 771-777.
7. Zakrzewski JL. Successful management of impending late graft failure in a thalassemic bone marrow transplant recipient. Haematologica 2002; 87: ECR32.
8. Tavil B, Kazik M, Kuskonmaz B, Cetin M, Uckan D. A prompt graft-versus-thalassemia effect upon withdrawal of cyclosporine A in a child who received allogenic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 315-316.
9. Collins Jr RH, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
10. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
11. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
12. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
13. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graftversus-host disease. Blood 1995; 86: 1261-1268.
14. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004; 33: 815-821.
15. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1705.
16. Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B et al. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. Br J Haematol 2005; 128: 649-658.
17. Yoshimi A, Bader P, Matthes-Martin S, Starý J, Sedlacek P, Duffner U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19: 971-977. (Pubitemid 40862007)
18. Willasch A, Hoelle W, Kreyenberg H, Niethammer D, Handgretinger R, Lang P et al. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica 2006; 91: 788-794.
19. Aker M, Kapelushnik J, Pugatsch T, Naparstek E, Ben-Neria S, Yehuda O et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bne marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998; 20: 145-148.
20. Baron F, Dresse MF, Beguln Y. Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic SCT for sickle cell disease. Transfusion 2000; 40: 1071-1073.
21. Ho HK, Chiang AK, Kwong YL, Chan GC, Lau YL, Ha SY. Pre-emptive treatment of early unstable mixed chimerism in a Chinese thalassaemia major patient by graded peripheral blood stem cell infusions. Haematologica 2003; 88: 5-7.
22. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840-844.
23. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/ efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979-987.
24. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104: 1201-1203.
25. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414-421.
26. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89: 3113-3117.
27. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
28. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
29. Fan Y, Xiao YB, Weng YG. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transplant Proc 2009; 41: 1821-1824.